Back to School: How biopharma can reboot drug development. Access exclusive analysis here

PRX-03140: Phase IIa data

In a 2-week, double-blind, U.S. Phase IIa trial in 80 patients, 150 mg of PRX-03149 monotherapy improved mean

Read the full 187 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE